向日葵：关于筹划重大资产重组的进展公告

Core Viewpoint - The company plans to acquire 100% equity of Zhangzhou Xipu Material Technology Co., Ltd. and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment, which is expected to constitute a related party transaction and a major asset restructuring, but not a restructuring listing [2] Group 1 - The transaction is currently undergoing auditing, evaluation, and due diligence processes [2] - The company is in continuous communication and negotiation with relevant parties regarding the major asset restructuring [2] - A board meeting will be convened to review the transaction after the completion of the relevant auditing and evaluation work [2] Group 2 - The company will hold a shareholders' meeting to deliberate on the proposals related to this transaction [2] - The company will fulfill subsequent procedures and information disclosure obligations in accordance with relevant laws and regulations [2]